Nanjing Hicin Pharmaceutical Co., Ltd

Nanjing Hicin Pharmaceutical Co. , Ltd. is focused on developing, producing, and distributing pharmaceutical products, including innovative drug formulations and health management solutions for various medical needs. Founded in 2003 in Nanjing, China, Nanjing Hicin Pharmaceutical Co.

, Ltd. specializes in pharmaceuticals, showcasing a commitment to quality health solutions. The company has engaged in three funding rounds, with the most recent being an IPO in January 2017, raising CNY 222. 2 million.

The firm operates without known subsidiaries or changes in business strategy since its inception. Nanjing Hicin Pharmaceutical Co. , Ltd. specializes in the development, production, and distribution of a diverse range of pharmaceutical products, including prescription medications, over-the-counter pharmaceuticals, and health supplements.

These offerings address various medical needs, with a focus on chronic diseases and acute health conditions, targeting therapeutic areas such as cardiology, oncology, and dermatology. The company serves a broad client base, which includes healthcare providers, hospitals, and pharmacies, and is expanding into international markets, particularly Southeast Asia and Europe. Nanjing Hicin Pharmaceutical Co. , Ltd.

generates revenue primarily through direct sales to healthcare institutions, retail pharmacies, and partnerships with wholesalers. The company's business model is predominantly B2B, fostering long-term relationships with clients for consistent supply of pharmaceutical products. Revenue is derived from bulk orders and recurring supply agreements, which support steady cash flow, while pricing aligns with market standards reflecting product efficacy and patient care. Nanjing Hicin Pharmaceutical Co.

, Ltd. plans to introduce new product lines targeting specific therapeutic areas, with anticipated launches following the IPO funding in early 2017. The company aims to expand into new markets in Southeast Asia and Europe, leveraging the funds raised to support these initiatives. The CNY 222.

3 million raised during the IPO will facilitate the development of additional innovative drug formulations and enhance its distribution capabilities in the targeted regions.